Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 CAD | -0.18% |
|
-5.26% | +4.05% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.05% | 400M | |
+15.72% | 77.62B | |
+13.65% | 8.98B | |
-24.30% | 4.33B | |
+12.79% | 4.21B | |
+31.45% | 4.1B | |
+10.97% | 2.19B | |
-30.57% | 2.04B | |
+8.99% | 1.94B | |
-45.76% | 1.69B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO